At a glance
- Originator Novartis
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Inflammation
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 31 Aug 1998 No-Development-Reported for Asthma (Unknown route)
- 31 Aug 1998 No-Development-Reported for Inflammation (Unknown route)